Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss

Launched by ACHE LABORATORIOS FARMACEUTICOS S.A. · Apr 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the safety and effectiveness of a new treatment called DNN.22.17.036 for men experiencing pattern hair loss, also known as androgenetic alopecia. The study will compare this new treatment to another one, identified as 10573048700, to see how well it works in helping to regrow hair. The trial is not yet recruiting participants but will focus on men aged 25 to 60 who have noticeable hair loss and a healthy scalp in the area being treated.

To be eligible for this trial, participants must be able to understand and agree to take part by signing a consent form. They should have a specific type of hair loss that meets certain criteria, including having at least 20% of hair in the shedding phase. However, men who have used certain medications for hair loss recently or have other medical conditions affecting their hair will not be able to join. If you qualify and choose to participate, you can expect to be part of a study that aims to improve treatment options for hair loss in men, helping to advance our understanding of this condition.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Ability to understand and consent to participate in this clinical research, expressed by signing the Informed Consent Form (ICF)
• • Male participants age 25 or older and 60 age or younger
• • Participants who have an intact scalp in the area of product analysis
• • Participants with androgenetic alopecia (AGA) with AGA Norwood-Hamilton Scale \> II
• • Participants with at least 20% telogen effluvium of evaluated by Tricholab
• Exclusion Criteria:
• • Participants who have used immunosuppressants in the 3 months prior to signing the ICF
• • Participants with other causes of hair loss or scalp dermatoses
• • Participants who have received hair loss treatment in the last 6 months
• • Participants with uncontrolled medical conditions, kidney and liver disease
• • Participants with a history of hair transplantation, malignancy, hematologic disorders, thyroid dysfunction, malnutrition, and other dermatologic disorders that contribute to hair loss